| Wissenschaftl. Titel | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradentitis suppurativa |
| Erkrankung |
Haut:
Acne inversa
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 07.11.2024 Admin04
geändert 06.01.2025 Admin02